503 related articles for article (PubMed ID: 29268619)
1. Isatuximab plus pomalidomide/dexamethasone versus pomalidomide/dexamethasone in relapsed/refractory multiple myeloma: ICARIA Phase III study design.
Richardson PG; Attal M; Campana F; Le-Guennec S; Hui AM; Risse ML; Corzo K; Anderson KC
Future Oncol; 2018 May; 14(11):1035-1047. PubMed ID: 29268619
[TBL] [Abstract][Full Text] [Related]
2. Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study.
Attal M; Richardson PG; Rajkumar SV; San-Miguel J; Beksac M; Spicka I; Leleu X; Schjesvold F; Moreau P; Dimopoulos MA; Huang JS; Minarik J; Cavo M; Prince HM; Macé S; Corzo KP; Campana F; Le-Guennec S; Dubin F; Anderson KC;
Lancet; 2019 Dec; 394(10214):2096-2107. PubMed ID: 31735560
[TBL] [Abstract][Full Text] [Related]
3. Isatuximab plus pomalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma according to prior lines of treatment and refractory status: ICARIA-MM subgroup analysis.
Bringhen S; Pour L; Vorobyev V; Vural F; Warzocha K; Benboubker L; Koh Y; Maisnar V; Karlin L; Pavic M; Campana F; Le Guennec S; Menas F; van de Velde H; Richardson PG
Leuk Res; 2021 May; 104():106576. PubMed ID: 33839618
[TBL] [Abstract][Full Text] [Related]
4. Isatuximab for relapsed/refractory multiple myeloma: review of key subgroup analyses from the Phase III ICARIA-MM study.
Richardson PG; Harrison SJ; Bringhen S; Schjesvold F; Yong K; Campana F; Le-Guennec S; Macé S; Dimopoulos MA
Future Oncol; 2021 Dec; 17(34):4797-4812. PubMed ID: 34521277
[TBL] [Abstract][Full Text] [Related]
5. Subgroup analysis of ICARIA-MM study in relapsed/refractory multiple myeloma patients with high-risk cytogenetics.
Harrison SJ; Perrot A; Alegre A; Simpson D; Wang MC; Spencer A; Delimpasi S; Hulin C; Sunami K; Facon T; Vlummens P; Yong K; Campana F; Inchauspé M; Macé S; Risse ML; van de Velde H; Richardson P
Br J Haematol; 2021 Jul; 194(1):120-131. PubMed ID: 34036560
[TBL] [Abstract][Full Text] [Related]
6. A phase 1b study of isatuximab plus pomalidomide/dexamethasone in relapsed/refractory multiple myeloma.
Mikhael J; Richardson P; Usmani SZ; Raje N; Bensinger W; Karanes C; Campana F; Kanagavel D; Dubin F; Liu Q; Semiond D; Anderson K
Blood; 2019 Jul; 134(2):123-133. PubMed ID: 30862646
[TBL] [Abstract][Full Text] [Related]
7. Pomalidomide and Low-Dose Dexamethasone Improves Health-Related Quality of Life and Prolongs Time to Worsening in Relapsed/Refractory Patients With Multiple Myeloma Enrolled in the MM-003 Randomized Phase III Trial.
Weisel K; Dimopoulos M; Song KW; Moreau P; Palumbo A; Belch A; Schey S; Sonneveld P; Sternas L; Yu X; Amatya R; Gibson CJ; Zaki M; Jacques C; San Miguel J
Clin Lymphoma Myeloma Leuk; 2015 Sep; 15(9):519-30. PubMed ID: 26149712
[TBL] [Abstract][Full Text] [Related]
8. Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): follow-up analysis of a randomised, phase 3 study.
Richardson PG; Perrot A; San-Miguel J; Beksac M; Spicka I; Leleu X; Schjesvold F; Moreau P; Dimopoulos MA; Huang JS; Minarik J; Cavo M; Prince HM; Malinge L; Dubin F; van de Velde H; Anderson KC
Lancet Oncol; 2022 Mar; 23(3):416-427. PubMed ID: 35151415
[TBL] [Abstract][Full Text] [Related]
9. Isatuximab: A Review of Its Use in Multiple Myeloma.
Frampton JE
Target Oncol; 2021 Sep; 16(5):675-686. PubMed ID: 34351561
[TBL] [Abstract][Full Text] [Related]
10. Isatuximab plus carfilzomib/dexamethasone versus carfilzomib/dexamethasone in patients with relapsed/refractory multiple myeloma: IKEMA Phase III study design.
Moreau P; Dimopoulos MA; Yong K; Mikhael J; Risse ML; Asset G; Martin T
Future Oncol; 2020 Jan; 16(2):4347-4358. PubMed ID: 31833394
[TBL] [Abstract][Full Text] [Related]
11. A phase 1b study of isatuximab plus lenalidomide and dexamethasone for relapsed/refractory multiple myeloma.
Martin T; Baz R; Benson DM; Lendvai N; Wolf J; Munster P; Lesokhin AM; Wack C; Charpentier E; Campana F; Vij R
Blood; 2017 Jun; 129(25):3294-3303. PubMed ID: 28483761
[TBL] [Abstract][Full Text] [Related]
12. Clinical efficacy of daratumumab, pomalidomide, and dexamethasone in patients with relapsed or refractory myeloma: Utility of re-treatment with daratumumab among refractory patients.
Nooka AK; Joseph NS; Kaufman JL; Heffner LT; Gupta VA; Gleason C; Boise LH; Lonial S
Cancer; 2019 Sep; 125(17):2991-3000. PubMed ID: 31090928
[TBL] [Abstract][Full Text] [Related]
13. The European medicines agency review of pomalidomide in combination with low-dose dexamethasone for the treatment of adult patients with multiple myeloma: summary of the scientific assessment of the committee for medicinal products for human use.
Hanaizi Z; Flores B; Hemmings R; Camarero J; Sancho-Lopez A; Salmonson T; Gisselbrecht C; Laane E; Pignatti F
Oncologist; 2015 Mar; 20(3):329-34. PubMed ID: 25673103
[TBL] [Abstract][Full Text] [Related]
14. Pomalidomide with or without dexamethasone for relapsed/refractory multiple myeloma in Japan: a retrospective analysis by the Kansai Myeloma Forum.
Matsumura-Kimoto Y; Kuroda J; Kaneko H; Kamitsuji Y; Fuchida SI; Nakaya A; Shibayama H; Uoshima N; Yokota I; Uchiyama H; Yagi H; Kosugi S; Matsui T; Ishikawa J; Matsuda M; Ohta K; Iida M; Tanaka H; Kobayashi M; Wada K; Shimazaki C; Nomura S; Imada K; Hino M; Matsumura I; Kanakura Y; Takaori-Kondo A;
Int J Hematol; 2018 May; 107(5):541-550. PubMed ID: 29380179
[TBL] [Abstract][Full Text] [Related]
15. Safe and prolonged survival with long-term exposure to pomalidomide in relapsed/refractory myeloma.
Fouquet G; Pegourie B; Macro M; Petillon MO; Karlin L; Caillot D; Roussel M; Arnulf B; Mathiot C; Marit G; Kolb B; Stoppa AM; Brechiniac S; Richez V; Rodon P; Banos A; Wetterwald M; Garderet L; Royer B; Hulin C; Benbouker L; Decaux O; Escoffre-Barbe M; Fermand JP; Attal M; Avet-Loiseau H; Moreau P; Facon T; Leleu X;
Ann Oncol; 2016 May; 27(5):902-7. PubMed ID: 26787238
[TBL] [Abstract][Full Text] [Related]
16. Isatuximab-Pomalidomide-Dexamethasone Versus Pomalidomide-Dexamethasone in East Asian Patients With Relapsed/Refractory Multiple Myeloma: ICARIA-MM Subgroup Analysis.
Sunami K; Ikeda T; Huang SY; Wang MC; Koh Y; Min CK; Yeh SP; Matsumoto M; Uchiyama M; Iyama S; Shimazaki C; Lee JH; Kim K; Kaneko H; Kim JS; Lin TL; Campana F; Tada K; Iida S; Suzuki K;
Clin Lymphoma Myeloma Leuk; 2022 Aug; 22(8):e751-e761. PubMed ID: 35641409
[TBL] [Abstract][Full Text] [Related]
17. An evaluation of isatuximab, pomalidomide and dexamethasone for adult patients with relapsed and refractory multiple myeloma.
Piggin A; Prince HM
Expert Rev Hematol; 2021 May; 14(5):419-427. PubMed ID: 33945375
[TBL] [Abstract][Full Text] [Related]
18. EMA Review of Isatuximab in Combination with Pomalidomide and Dexamethasone for the Treatment of Adult Patients with Relapsed and Refractory Multiple Myeloma.
Delgado J; Zienowicz M; van Hennik PB; Moreau A; Gisselbrecht C; Enzmann H; Pignatti F
Oncologist; 2021 Nov; 26(11):983-987. PubMed ID: 34213061
[TBL] [Abstract][Full Text] [Related]
19. Multiagent therapy with pomalidomide, bortezomib, doxorubicin, dexamethasone, and daratumumab ("Pom-PAD-Dara") in relapsed/refractory multiple myeloma.
Zhou X; Steinhardt MJ; Grathwohl D; Meckel K; Nickel K; Leicht HB; Krummenast F; Einsele H; Rasche L; Kortüm KM
Cancer Med; 2020 Aug; 9(16):5819-5826. PubMed ID: 32608149
[TBL] [Abstract][Full Text] [Related]
20. Overall survival of relapsed and refractory multiple myeloma patients after adjusting for crossover in the MM-003 trial for pomalidomide plus low-dose dexamethasone.
Morgan G; Palumbo A; Dhanasiri S; Lee D; Weisel K; Facon T; Delforge M; Oriol A; Zaki M; Yu X; Sternas L; Jacques C; Akehurst R; Offner F; Dimopoulos MA
Br J Haematol; 2015 Mar; 168(6):820-3. PubMed ID: 25403264
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
